Document:

Exhibit

Exhibit 10.1

	
		
	
	

Compass Minerals 
9900 W. 109th Street, Suite 100 
Overland Park, KS 66210 
www.compassminerals.com 
913-344-9200

March 21, 2017

Mr. Patrick Douglas Linehan
XXXXXXX
XXXXX, XX  XXXXX

Dear Doug,

I am pleased to confirm that Compass Minerals International, Inc. (CMP) wishes to invite you to join our leadership team by making you this offer of employment.  If you accept this offer, your title will be Chief Financial Officer.  You will begin work on April 3, 2017.  This position will report to me and will be located at our corporate office in Overland Park, Kansas.

The Chief Financial Officer is a full-time exempt position.  Your annual starting salary will be $450,000.00.  In addition to your base salary, you will be eligible to participate in the CMP Management Annual Incentive Program (MAIP), prorated from your start date for the 2017 year, with a targeted bonus equal to 60% of your base salary. You will also be eligible to receive equity awards as part of the CMP Long Term Incentive Program (LTIP) (granted in April of each year) subject to board approval.  For your position, the LTIP target is 150% of your base salary.  

Upon joining, you will receive your full 2017 LTIP award valued at approximately $675,000.00.  This award will be delivered as follows:  25% as stock options, 25% as restricted stock units (RSUs), 25% as performance share units (PSUs) with a rTSR metric and 25% as PSUs with an ROIC metric.  These grants will be subject to the same performance hurdles and vesting terms as all other 2017 annual grants.

In addition, upon joining you will also be granted a one-time RSU award valued at approximately $225,000.00 with the same performance metric (2017 adjusted EBITDA) and three year cliff vesting as all other 2017 annual RSU grants.

To facilitate your relocation to the Kansas City area, you are eligible for our Executive Relocation benefit.  Please note that this does not include any buy-out option of your current home or home equity loss guarantee.  A copy of the relocation plan will be provided to you.

Effective on your hire, you will be eligible for four weeks (20 days) of paid vacation annually.  

You will be offered a Change in Control Agreement and required to sign a Restrictive Covenant Agreement in the forms enclosed, along with other standard employment documents applicable to other CMP employees.

Enclosed you will also find a benefit packet to familiarize you with benefits that are available to you and your family once you join CMP. In addition, you shall be entitled to an annual executive physical and eligible to participate in the Executive Disability Plan.

This offer of employment is conditional upon the verification of a satisfactory background investigation, verification of your authorization to work in the U.S., satisfactorily passing a drug screen, and the execution of the Restrictive Covenant Agreement.

	
		
	
	

Compass Minerals 
9900 W. 109th Street, Suite 100 
Overland Park, KS 66210 
www.compassminerals.com 
913-344-9200

The Immigration and Control Act of 1986 requires employers to verify that every new hire is either a U.S. citizen or eligible to be employed in this country.  We are required to examine and will copy any one of the following:   US passport, certification of U.S. citizenship or naturalization, a valid foreign passport authorizing U.S. employment, a resident alien card containing employment, a resident alien card containing employment authorization, or other document designated by the Immigration and Naturalization Service. 

Alternatively, verification can be accomplished by providing two forms of documentation one which established identity and one, which establishes employment eligibility.  Examples of documents, which show employment eligibility:  Social Security card or birth certificate; and examples, which are proof of identity:  driver’s license or other state issued card, which contain photograph or other identifying information.  The above documentation must be presented prior to commencing employment.  Please bring the appropriate items on your start date.

Please sign the duplicate copy of this letter, acknowledging your acceptance and anticipated employment date, and complete the enclosed Application for Employment, and return to me by March 24, 2017.

I look forward to you joining Compass Minerals.

Sincerely,

/s/ Fran Malecha

Fran Malecha
President and CEO

By signing this letter below, you understand and agree that your employment with the company is at-will.  That is, your employment is not for any specified duration and you or the Company may terminate it, at any time, with or without cause and without notice.

/s/ Patrick Doug Linehan                                                           Employment date:  April 3, 2017
Patrick Doug Linehan      Date 3/24/17EX-10.4.(b)

 Exhibit 10.4(b) 

June 1, 2016 
 Willowbridge
Associates Inc. 
 101 Morgan Lane - Suite 180 

Plainsboro, N.J. 08536 

Attention: Mr. Steve R. Crane 
  

	 	Re:	 Management Agreement Renewals 

Dear Mr. Crane: 
 We are
writing with respect to your management agreements concerning the commodity pools to which reference is made below (the “Management Agreement”). We are extending the term of the Management Agreement through June 30, 2017 and all other
provisions of the Management Agreements will remain unchanged. 
  

	 	•	 	 Tactical Diversified Futures Fund L.P. 

 

	 	•	 	 CMF Willowbridge Master Fund L.P. 

 

	 	•	 	 Emerging CTA Portfolio LP 

 

	 	•	 	 Orion Futures Fund L.P. 

 

	 	•	 	 Managed Futures Premier Macro L.P. 

Please acknowledge receipt of this modification by signing one copy of this letter and returning it to the attention of
Mr. Patrick T. Egan at 522 Fifth Avenue – 7th Floor, New York, NY 10036 or fax to 866-428-9026. If you have any questions, I can be reached at 212-296-6808 or contact Jack Yuen at 212-296-1320. 

Very truly yours, 
  

			
	 CERES MANAGED FUTURES LLC

		
	 By:
	 	 /s/ Patrick T. Egan

		 	 Patrick T. Egan

		 	 President and Director

	
	WILLOWBRIDGE ASSOCIATES INC.
		
	 By:
	 	 /s/ Steven R. Crane

		
	 Print Name:
	 	 Steven R. Crane

		
		 	 Willowbridge Associates Inc.

 PE/kgEX-10.4(C)

 Exhibit 10.4(c) 

June 1, 2016 
 Aventis Asset Management, LLC 

2150 E. Lake Cook Road, Suite 720 
 Buffalo Grove, IL 60089 

Attention: Mr. Steve Hwang 
 Re: Management Agreement
Renewals 
 Dear Mr. Hwang: 
 We are
writing with respect to your management agreements concerning the commodity pools to which reference is made below (the “Management Agreements”). We are extending the term of the Management Agreements through June 30, 2017 and all
other provisions of the Management Agreements will remain unchanged. 
  

	 	•	 	 Commodity Advisors Fund LP. 

 

	 	•	 	 MB Master Fund L.P. 

 

	 	•	 	 Institutional Futures Portfolio L.P. 

 

	 	•	 	 MSSB Spectrum Strategic L.P. 

 

	 	•	 	 Managed Futures Premier Aventis II L.P. 

 

	 	•	 	 MSMF Custom Solutions Fund L.P. 

Please acknowledge receipt of this modification by signing one copy of this letter and returning it to the attention of
Mr. Patrick T. Egan at 522 Fifth Avenue – 7th Floor, New York, NY 10036 or fax to 866-428-9026. If you have any questions, I can be reached at 212-296-6808 or contact Jack Yuen at
212-296-1320. 
  

			
	Very truly yours,
	
	CERES MANAGED FUTURES LLC
		
	By:	 	/s/ Patrick T. Egan
		 	Patrick T. Egan
		 	President and Director

  

			
	AVENTIS ASSET MANAGEMENT, LLC
		
	By:	 	/s/ Steve Hwang

			
	Print Name:	 	  Steve Hwang, COO
	PE/kgExhibit 10.7

 

AMENDMENT NO. 1 TO DEFINITIVE LICENSE
AND TRANSFER AGREEMENT

 

This Amendment No. 1 to Definitive License
and Transfer Agreement (this “Amendment”), effective as of January 3, 2017 (the “Amendment Effective
Date”), is by and between Enumeral Biomedical Holdings, Inc., a Delaware corporation with a place of business at 200
Cambridge Park Drive, Suite 2000, Cambridge, MA 02140 (“Enumeral”) and Pieris Pharmaceuticals, Inc., a Nevada
corporation with a place of business at 255 State Street, 9th Floor, Boston, MA 02109 and Pieris Pharmaceuticals GmbH,
a German company with a place of business at Lise-Meitner-Strasse 30, 85354 Freising, Germany (collectively, and together with
their Affiliates, “Pieris”), under which the Parties mutually agree to modify and amend the Definitive License
and Transfer Agreement between the Parties, with an Effective Date of June 6, 2016 (the “Agreement”), as set
forth below. Capitalized terms used in the Amendment but not defined herein shall have the meanings set forth in the Agreement.

 

WHEREAS, under the
Agreement, Enumeral granted Pieris a non-exclusive right and license under certain Enumeral IP granting Pieris the right to exploit
such Enumeral IP, including through the grant of sublicenses, subject to certain restrictions; and

 

WHEREAS, the Parties
hereto wish to amend the terms of the Agreement to protect the Sublicensee’s rights in the event the Agreement is terminated
for any reason.

 

NOW THEREFORE, the
parties hereby agree as follows:

 

		1.	Amendments. The Agreement is hereby amended as follows:

 

		1.1.	The following sentence shall be added to the end of Section 2.4 (Sublicenses) as a new sentence:
“Pieris shall furnish Enumeral with a true and accurate fully executed copy of any Sublicense and any amendments thereto
or default letters thereto, promptly after its or their execution. Pieris may keep confidential product targets, development plans,
patent numbers, the royalty percentage amounts, the amounts of any upfront, milestone or option payments, and the percentage amount
applied to any sublicense or similar economic terms from the Sublicense and any amendments thereto.”

 

		1.2.	The following is added to Section 9.5 (Effect of Termination):

 

b) Sublicenses.

 

(i) Any sublicense agreement(s)
entered into under Section 2.4 of this Agreement for the purpose of the development and commercialization of any drug or products
(each, a “Sublicense”) in effect as of the effective date of termination of this Agreement shall terminate (the “Termination
Date”), and such Sublicensee shall, at its option by providing written notice of its election to do so within forty-five
(45) days following the Termination Date, be a direct licensee under and subject to the terms and conditions of this Agreement
as if a signatory hereto, provided that: (i) the payment terms of the direct license will be those of this Agreement; (ii) the
Sublicensee is in good standing with respect to the Sublicense and was not itself the cause of the termination of this Agreement;
(iii) the rights granted to the Sublicensee shall be subject to the field restrictions and other limitations under the Sublicense
as if fully set forth herein; (iv) Enumeral and Sublicensee shall negotiate in good faith regarding the choice of law jurisdiction
for such direct license; (v) any diligence requirements on the part of such Sublicensee for the development of any product under
the Sublicense Agreement shall continue in addition to any diligence requirements under this Agreement; (vi) such Sublicensee has
expressly agreed to abide by this provision and assume the obligations under this Agreement; and (vii) such direct license between
Enumeral and the Sublicensee shall not place any additional obligations or restrictions (including but not limited to representations,
warranties, or liabilities) on Enumeral that are not included in this Agreement or that are beyond Enumeral’s obligations
under this Agreement without the prior written consent of Enumeral. By accepting such direct license, such Sublicensee releases
Enumeral from any claim or liability whether actual or contingent under any agreement with Pieris.

 

     

     

    

 

(ii)   In the event that a
Sublicense of any license granted to Pieris under this Agreement is terminated or rejected by or on behalf of Pieris under the
applicable provisions of any bankruptcy laws and Sublicensee is unable to make an election thereunder to continue the Sublicense,
then Enumeral hereby grants a direct license to Sublicensee under the terms of Section 9.5(b)(i) above, without any further action
of Pieris, provided that such action is not blocked or objected to in bankruptcy court, and further provided that this Agreement
is concurrently terminated in such bankruptcy action (or, if the Agreement is not so terminated, Pieris hereby waives any restrictions
to the contrary in the Agreement in order to permit such direct license).

 

(iii)  The Parties further acknowledge
and agree that any such Sublicensee shall be a third party beneficiary of this Agreement to the extent required to enforce its
rights under this Section 9.5(b).

 

2.           Scope. This Amendment supersedes
all proposals, negotiations, conversations and/or discussions between or among Parties relating to the subject matter of this Amendment
and all past dealing or industry custom. This Amendment shall be integrated in and form part of the Agreement effective as of the
Amendment Effective Date. Except for the foregoing modifications, the Agreement is hereby ratified and confirmed in accordance
with its original terms. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same agreement.

 

     

     

    

 

IN WITNESS WHEREOF, the Parties have caused
this Amendment to be executed by their duly authorized representatives as of the Amendment Effective Date.

 

	ENUMERAL BIOMEDICAL HOLDINGS, INC.	 	PIERIS PHARMACEUTICALS INC. 
	 	 	 
	By:  /s/ Matthew A. Ebert	 	By:  /s/ Stephen Yoder
	 	 	 
	Name:  Matthew A. Ebert	 	Name: Stephen Yoder
	 	 	 
	Title:  General Counsel  	 	Title: President and CEO
	 	 	 
	Date: January 3, 2017	 	Date: January 3, 2017
	 	 	 
	 	 	PIERIS PHARMACEUTICALS GMBH
	 	 	 
	 	 	By: /s/ Stephen Yoder
	 	 	 
	 	 	Name: Stephen Yoder
	 	 	 
	 	 	Title: Managing Director
	 	 	 
	 	 	Date: January 3, 2017

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]